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Abstract
New regenerative materials and approaches need to be 
assessed through reliable and comparable methods for 
rapid translation to the clinic. There is a considerable need 
for proven in vitro assays that are able to reduce the burden 
on animal testing, by allowing assessment of biomaterial 
utility predictive of the results currently obtained through in 
vivo studies. The purpose of this multicentre review was to 
investigate the correlation between existing in vitro results 
with in vivo outcomes observed for a range of biomaterials. 
Members from the European consortium BioDesign, 
comprising 8 universities in a European multicentre study, 
provided data from 36 in vivo studies and 47 in vitro assays 
testing 93 different biomaterials. The outcomes of the in 
vitro and in vivo experiments were scored according to 
commonly recognised measures of success relevant to each 
experiment. The correlation of in vitro with in vivo scores 
for each assay alone and in combination was assessed. A 
surprisingly poor correlation between in vitro and in vivo 
assessments of biomaterials was revealed indicating a clear 
need for further development of relevant in vitro assays. 
There was no significant overall correlation between in 
vitro and in vivo outcome. The mean in vitro scores revealed 
a trend of covariance to in vivo score with 58 %. The 
inadequacies of the current in vitro assessments highlighted 
here further stress the need for the development of novel 
approaches to in vitro biomaterial testing and validated 
pre-clinical pipelines.
Keywords: in vivo, in vitro, correlation, biomaterials, 
multicentre study.
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Introduction
Researchers and key decision-makers have enthusiastically 
endorsed the therapeutic promise of regenerative 
medicine. The anticipated clinical impact has led 
to considerable research investment and a resultant 
proliferation of regenerative medicine-related innovations 
and technologies. One of the most mature research areas 
in this field is the development of innovative biomaterials 
for bone regeneration.
 Over the last decade, a plethora of increasingly advanced 
biomaterials, designed to provide specific mechanical or 
morphological properties and kinetics combined with an 
expansive range of biomimetic modifications have been 
developed for use (in isolation or in combination with 
cell therapy) in bone regeneration (Billstrom et al., 2013; 
Garcia-Gareta et al., 2015; Gibbs et al., 2014). However, 
the range of materials and resultant potential therapies 
present a significant burden for pre-clinical in vivo testing 
and subsequent clinical translation. The challenge for 
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regenerative medicine is analogous to that faced in toxicity 
testing where the escalating number of new chemical 
entities (NCEs) and the extensive requirement for animal 
testing had the result that only a fraction of NCEs were 
considered for further evaluation. As with NCE toxicity 
testing, moving away from the use of, or at least reducing, 
animal testing is a critical imperative in regenerative 
medicine.
 Both ethical and efficiency concerns underlie this 
imperative. Animal behaviour and neurophysiology 
appears increasingly to validate the sentiments (not the 
methods) of the animal rights movement. For example, 
a study by Bartal et al. showed pro-social behaviour 
in rats (Bartal et al., 2011) and a special vocalisation 
of adolescent rats is proposed to have an evolutionary 
relation to the joyfulness of children’s laughter (Bering 
2012; Panksepp and Burgdorf, 2003). In response to this 
increasing awareness Russell and Burch’s 3Rs initiative is 
being implemented legislatively and adopted by funders 
and governments to enable: (1) reduction of the number of 
animals used, (2) refinement of experiments to minimise 
animal suffering and distress and (3) replacement of animal 
testing by alternative in vitro approaches (Russell and 
Burch, 1959).
 The extensive fiscal and time expenditure of animal 
experimentation has provided a further significant driver 
behind the development for an increased reliance on 
relatively high throughput in vitro alternatives to animal 
testing. In a systematic review, Morgan et al. compared 
cost estimates of drug developments and observed the 
cost estimates of preclinical work ranged from USD$ 46 
to USD$ 165 billion (Morgan et al., 2011). To date, there 
remains no gold standard for the estimation of the costs 
spanning from developing a drug through to clinical 
implementation.
 Successful replacement and reduction of animal 
procedures has been achieved in various fields, as indicated 
above and perhaps most notably in toxicology testing, 
through improvements to in vitro and in silico models 
(Langley et al., 2007; Vodovotz et al., 2006) as well as 
improvements in sharing of existing data in order to inform 
new studies (Knight, 2008). The same development is 
necessary in the field of regenerative materials, which 
needs to be evaluated with reliable and comparable 
methods. One possibility is to draw conclusions from 
previously performed experiments/studies through a 
direct correlation of in vitro versus in vivo outcomes of 
biomaterials. Are there parameters that have been measured 
within in vitro assays that correlate with objective in vivo 
outcomes?
 It is important to note in vitro and in vivo evaluations 
will likely both remain critically important in the 
development of a clinical therapeutic entity. In vivo 
experiments allow rigorous assessment of the material-
cell/host interaction and the regenerative efficacy of 
a biomaterial strategy. The wide range of parameters 
provided through in vivo assessment are important for 
osteo-regenerative materials, as bone itself is a complex 
organ responsible for protection, muscle attachment, 
calcium homeostasis and as a centre of haematopoiesis. 
Bone is a highly organised structure that constantly 
remodelled and optimised to allow mechanical loading 
and to meet the demand for calcium by a strictly controlled 
interplay between osteoblasts and osteoclasts, conducted by 
osteocytes (Bonewald 2006; Bonewald 2011; Frost 1994). 
If a defect is not too large, bone has an inherent ability to 
regenerate completely without scar-formation. This self-
regeneration is orchestrated by a number of cytokines and 
involves a variety of cells where the immune system plays 
an important part (Marsell and Einhorn 2009; Marsell and 
Einhorn 2011). Bone regeneration needs certain conditions, 
where vascularisation, stabilisation, scaffolding, cell 
signalling and progenitor cells are imperative requirements 
(Giannoudis et al., 2007; Giannoudis et al., 2008). The 
implanted biomaterial in vivo will encounter the cells of the 
immune system that will degrade the material or contain 
the material within a fibrous tissue. Furthermore, the 
surrounding tissue will provide a mechanical environment 
that will both affect the material as well as the cell response. 
The material will have the possibility to affect stem and 
progenitor cells in terms of lineage fate and function. It 
is this wide range of parameters that in vivo models are 
designed to encompass. In vitro assays, on the other hand, 
typically, serve as screening assays that allow experimental 
assessment used as predictive methods for rapid screening 
of the host response to the biomaterial. The International 
Organisation for Standardisation (ISO) and ASTM 
International have developed standards that are specific 
for in vitro biocompatibility and cytotoxicity tests (Müller 
2007) and for standardised assessment of biomaterials 
both in vitro and in vivo (F1983-14; F2721-09r14), which 
significantly increases the safety of the product. However, 
these standards are generally for medical devices and may 
not predict the bone regeneration of a specific biomaterial. 
A raft of standardised tissue culture techniques are used to 
observe cell compatibility where the toxicity of the material 
can be measured by, for example, cell survival, metabolic 
activity and cell growth. The effect of the material can be 
studied utilising cell differentiation where expression of 
genes and mRNA and cell surface markers are quantified 
(Ko et al., 2008).
 Though in vivo experiments will likely remain a critical 
aspect of biomaterial testing, in vitro assays need to play an 
increasingly important role in screening out biomaterials 
with inadequate properties prior to examination of more 
promising candidates in vivo. A key question to address 
is therefore: are current in vitro assessments proficient 
in fulfilling this role of pre-screening prior to in vivo 
assessment of bone regeneration? In this context, the 
term in vitro assessment refers both to the assay itself 
and the interpreted significance of the assay results that 
serve to inform further studies along the biomaterial 
testing pipeline. To address this question, the current study 
explores the correlation between researcher assessed, in 
vitro and in vivo outcomes of biomaterials tailored for bone 
in a European multicentre study between 8 universities that 
included 36 independent in vivo studies and 47 individual 
in vitro assays testing 93 biomaterial variables. The 
focus of this study is on the correlation between in vitro 
testing and early stage (i.e. small animal) in vivo models 
of bone regeneration in use across the consortium. In 
contrast to conventional literature based meta-analyses, 
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the multicentre approach adopted, though more limited 
in scope, allowed access to complete data sets. Critically, 
such datasets included the often unpublished negative data 
so vital for exploring in vitro-in vivo correlations.
Methods
Data collection
Members from the European consortium Biodesign, 
comprising 8 universities in a European multicentre study, 
kindly collated the data (Table 1) from both published and 
unpublished historical in vivo datasets. The scope of the 
data included was defined by completed in vivo datasets for 
the various biomaterial strategies tested. The in vitro assays, 
which constitute the subject of this study, were selected on 
the basis of their use by the member groups in the testing 
of their biomaterial strategies prior to or alongside these 
in vivo studies. The data included 36 in vivo experiments, 
47 in vitro experiments and 93 tested biomaterial variables.
 In vivo and in vitro outcomes for each experimental 
variable tested in an in vivo study were described 
qualitatively by the assessor on the basis of a range 
of expected positive and/or negative indications of 
regenerative outcome (e.g. high cell proliferation, evidence 
of cytotoxicity etc.) pre-defined for each assay by the 
assessor. On the basis of this qualitative assessment, the 
outcome of each variable for each in vitro and in vivo assay 
conducted was scored out of 5 (1 = poor, 5 = very good).
In vitro parameters assessed for correlation
Cell differentiation
Cell differentiation towards the osteogenic lineage 
can be quantified by measuring the activity of the cell 
marker alkaline phosphatase (ALP) (McComb et al., 
1979), a widely used non-specific assay for osteogenic 
differentiation. In this assay p-nitrophenyl phosphate is 
dephosphorylated by ALP into a yellow product with 
an absorbance that can be measured at a wavelength 
of 405 nm. ALP is highly expressed by osteoblasts and 
through the cleavage of pyrophosphate allows spontaneous 
mineralisation in the secreted osteoid (Millan 2013). A 
high activity of ALP is interpreted as a positive outcome as 
ALP plays a central role in the bio-mineralisation process 
of bone.
Biocompatibility
Several biocompatibility tests can be used for cell 
proliferation, cell viability, and cell attachment to 
distinguish material candidates that are of a biocompatible 
nature. A number of reagents are used and most of 
them are based on the same concept of measuring the 
metabolism by the reduction of a substrate. One common 
example is a tetrazolium compound that is mixed with 
phenazine methosulphate (MTS) (Goodwin et al., 1995). 
During cell metabolism, MTS is reduced by the activity 
of dehydrogenase to formazan that can be measured by 
visible light absorbance at 492 nm. Live dead staining 
is a widely used in vitro assay to measure the viability 
of cells. A fluorescent dye 5-chloromethylfluorescein 
diacetate (CMFDA) labels metabolically active cells and 
the membrane impermeable ethidium homodimer-1 labels 
DNA in apoptotic or damaged cells.
Gene expression
Osteogenic differentiation can be measured by quantifying 
the expression of specific genes expressed during 
osteoblastic differentiation. One of the key transcription 
factors is Runt-related transcription factor 2 (RUNX2) 
(van Wijnen et al., 2004), which at early stages induce 
the process of osteoblast differentiation and in later stages 
inhibits the same process. RUNX2 is important in skeletal 
morphogenesis and is involved in the expression of several 
bone matrix genes such osteocalcin, being an abundant 
protein found in bone provides useful markers to follow 
stem-progenitor differentiation. Genes that are expressed 
at later time points include, for example, osteopontin, 
involved in remodelling (Bruderer et al., 2014). Increased 
gene expression at the appropriate temporal stages is 
interpreted as a positive result.
Mineralisation assay
Calcium deposition of cell cultures can be quantified 
using alizarin red staining and serves as a measure of 
osteogenic differentiation, where a large amount of 
deposition is interpreted as a positive outcome (Dawson 
1926). This in vitro assay provides evaluation of the 
osteoblastic differentiation of progenitor cells as well 
as the functionality of the differentiated cell population 
(Gregory et al., 2004).
Table 1. Participating laboratories in the survey.
University Group principal investigator Country
AO Foundation Martin Stoddart Switzerland
Eidgenössische Technische Hochschule Ralph Müller Switzerland
Keele University Alicia El Haj United Kingdom
Ludwig Boltzmann Institute Heinz Redl Austria
University College London Robert Brown United Kingdom
University of Nottingham Kevin Shakesheff United Kingdom
University of Southampton Richard O. C. Oreffo United Kingdom
Uppsala University Sune Larsson, Jöns Hilborn Sweden
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In vivo models against which in vitro models were 
correlated
The purpose of this review article was to correlate the 
interpretation of in vitro results to in vivo outcomes 
observed for a range of biomaterials. A selection of in vivo 
models from the survey that had been used to evaluate 
biomaterials was correlated to the interpreted results of in 
vitro assays for the same biomaterials.
Segmental-defect models
Critical size segmental defects in rats and mice are 
frequently used to measure the osteoinductive capability 
of biomaterials for bone regeneration using a fixator that is 
either internal or external. The definition of a critical sized 
defect is an incapability of spontaneous healing (Hollinger 
and Kleinschmidt 1990). Addition of an inductive 
substance, that triggers bone formation, is necessary for 
bridging healing to occur. Einhorn et al. (1984) developed, 
in the 1980s, a rat segmental defect that consistently 
resulted in non-union when left untreated. The femoral 
defect was 6 mm long and stabilised with two proximal 
and two distal Steinmann pins. The defect was evaluated 
with radiographs and mechanical testing (Einhorn et al., 
1984). This femoral segmental defect was later reduced 
to a 5 mm long segmental critical size defect to evaluate 
the osteogenic potential of silk scaffolds combined with 
either human bone marrow stromal cells (HBMSCs) or a 
combination of HBMSCs and bone morphogenetic protein 
2 (BMP-2) (Meinel et al., 2006). The same combinations 
were used with the addition of pre-differentiated HBMSCs 
(Kirker-Head et al., 2007). Both studies assessed the 
healing capacity using micro-computed tomography 
(µCT), mechanical testing and histology.
 Both Kaipel et al. (2012) and Schutzenberger et al. 
(2012) used a 3 mm long segmental defect as a delayed 
union model in rats. The defect was stabilised with an 
internal plate fixator, while initial healing was prevented 
using a silicone spacer that was kept in the defect for 4 
weeks after which it was removed during a second surgery. 
Following removal of the spacer the defect was filled with 
either a BMP-2 fibrin carrier or the commercial available 
BMP-2 collagen carrier. The same defect was used in 
a similar study to evaluate the effect of applied growth 
factors of angiogenesis and osteogenesis in a fibrin clot. 
The bone forming capacity was evaluated by X-ray, µCT 
and mechanical testing (Kaipel et al., 2012; Schutzenberger 
et al., 2012). The results showed increased bone formation 
using BMP-2 in a fibrin clot. The study also showed that a 
fibrin scaffold with a sevenfold lower dose of BMP-2 could 
still provide equivalent results compared to the commercial 
BMP-2 product.
 Kanczler et al. ,  used the male MF-1 nu/nu 
immunodeficient mouse femur segmental defect model 
to study the enhancement of bone regeneration after 
implantation of HBMSCs seeded onto vascular endothelial 
growth factor (VEGF)/BMP-2 composite scaffolds 
(Kanczler et al., 2010) or biodegradable poly(D,L-lactide) 
(PLA) scaffolds (Kanczler et al., 2008) with VEGF 
incorporated. Bone formation was measured using µCT 
and histology with both materials providing enhanced 
regeneration of the segmental bone defect compared to 
groups without HBMSCs and growth factors. The same 
research group employed diffusion chambers that were 
implanted intraperitoneally in MF-1 nu/nu mice for 10 
weeks. The diffusion chambers afforded interaction with 
the in vivo milieu without ingrowth or response from 
the host cells and thus allowed evaluation of seeded 
HBMSCs on a biomimetic collagen scaffold and BMP-2-
encapsulated (PLA) scaffolds (Yang et al., 2003; Yang et 
al., 2004a; Yang et al., 2004b).
Subcutaneous models
The subcutaneous implant is a widely used model, usually, 
to assess the osteoconductive and osteoinductive properties 
of a material to develop ectopic bone. The disadvantage of 
the subcutaneous model is the perceived lack of clinical 
relevance and, typically, the absence of bone cells that can 
affect the potential bone formation capacity of a material. 
Nevertheless, the absence of local bone cells can also be 
advantageous and has been used for evaluation of HBMSCs 
that were seeded on solid hydroxyapatite and collagen 
scaffolds or in polysaccharide capsules (Dawson et al., 
2008; Pound et al., 2006). To visualise the vascularisation 
of tissue-engineered constructs containing HBMSCs/bone 
allograft and PLA, a subcutaneous model was used in 
athymic mice. The constructs were impacted and implanted 
subcutaneously and after 4 weeks perfused in vivo with 
Microfil prior to µCT scanning (Bolland et al., 2008). The 
subcutaneous implants provide a rapid screening model for 
“biocompatibility” and osteo-inductivity/-conductivity and 
have been used for bioactive materials carrying growth 
factors such as Bone morphogenetic proteins (BMPs) 
(Kisiel et al., 2013). Several implants can be compared 
in the same individual giving paired data and hence the 
possibility to reduce the number of animals used while 
achieving valid information.
Critical sized cranial-defect models
Critical sized cranial defects (CSD) have been employed 
for bone material evaluation for over fifty years. As far back 
as 1957, Ray and Hollow described a cranial defect in rats 
that was treated with frozen intact bone, deproteinised bone 
or decalcified bone. Subsequently, Ko et al. used an 8 mm 
cranial defect in rats. However, the cranial defect model 
is technically challenging with risk to the dura mater as 
well as a risk of severe haemorrhage due to the presence of 
major blood vessels in the cranial bone (Ko et al., 2008). 
Ray and Holloway circumvented these issues by creating 
smaller defects on the lateral side of the cranium to avoid 
the underlying blood vessels (Ray and Holloway, 1957). 
Given the smaller defect size (4 mm), two defects can be 
generated in the parietal bones lateral to the mid-sagittal 
suture in the cranium of rats and mice, allowing paired 
analysis and thus enhancing statistical power (Meinel et 
al., 2005; Ventura et al., 2014).
Femoral condyle-defect model
The use of large animal models has also been examined. 
Ueng et al. created bone cavities in the lateral femoral 
condyles of rabbits and implanted beads of alginate mixed 
with PKH 26-labelled rabbit mesenchymal stem cells and 
vancomycin (Ueng et al., 2007). The beads of alginate 
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demonstrated sustained release of vancomycin over 14 d 
and osteogenic differentiation of cultured mesenchymal 
stem cells (MSCs) in the alginate carrier matrix. The 
implanted MSCs contributed with newly formed bone 
in vivo.
Data analysis
The overall correlation between in vitro and in vivo 
outcomes across the entire dataset was characterised by 
sorting and then categorising the data according to in vitro 
score, before plotting the mean in vivo score obtained for 
each respective in vitro score category. Thus, for every 
biomaterial variable scoring 1, 2, 3 etc. in vitro, the 
corresponding in vivo scoring was listed and the mean 
plotted against each respective in vitro score ‘category’. 
The same approach was adopted with the in vivo scores, 
which were again categorised to obtain the corresponding 
mean in vitro score for correlation.
 As well as an overall assessment of in vitro – in vivo 
correlation, the in vitro outcomes were sorted into sub-
groups representing individual classes of in vitro assay. 
The sub-groups were, i) Group 1; alkaline phosphatase 
activity, ii) Group 2; biocompatibility, iii) Group 3; calcium 
deposition iv) Group 4 and 5; gene expression of early 
markers and late markers respectively (Table 2). The in 
vitro outcome scores of the material were subsequently 
correlated with the in vivo outcome scores. Further, the in 
vitro assay groups were combined in pairs to investigate if a 
combination of in vitro assays provided a better prediction 
of in vivo outcome over single assays for correlation.
 For the purpose of the remaining part of this paper, 
the following terms are used as defined below: Groups 
consist of in vitro assay (See Table 2), which were used 
as parameters to correlate the predictive outcome.
Null hypothesis:  No correlation exists between in vivo  
   and in vitro outcomes.
Hypothesis:  Specific in vitro parameters or a   
   combination of in vitro parameters can  
   be used to predict material in vivo   
   outcomes.
Correlation
Pearson’s correlation was used to test for significant linear 
relationships between the in vitro and in vivo outcome 
(n > 5). Coefficients of determination (R2) delineating the 
percentage of shared variance are presented and a p-value 
of < 0.05 was considered significant.
Sensitivity and specificity
The data for each in vitro assay groups was split into 
quartiles to distinguish false positives, false negatives, 
true positives and true negatives where a positive result 
was defined as one that scored > 2.5 and a negative result 
was defined as one that scored < 2.5 (Fig. 3a). Fisher’s 
exact test was performed to measure the sensitivity and 
specificity of the various groups. A confidence interval of 
95 % was used.
Results and Discussion
Despite considerable consensus in how assays were 
interpreted, the current analysis demonstrated no 
significant overall correlation between in vitro outcomes 
and in vivo outcomes.
 The mean in vitro scores revealed a trend of covariance 
to in vivo scores with 58 %. The mean in vivo scores shared 
51 % of variance when correlated to the in vitro categories 
(Fig. 1a). Analysis of the different in vitro techniques; 
biocompatibility, cell differentiation, gene expression 
of early markers, gene expression of late markers and 
calcium deposition demonstrated a covariance of less 
than 10 % (Fig. 1b-f). To determine if combinations of in 
vitro assays could predict the in vivo outcome, a selection 
was made that included materials evaluated by more than 
one in vitro assay. The medians of the combined in vitro 
scores were subsequently correlated to the in vivo outcomes 
(Fig. 2a-f). On analysis, less than 10 % covariance was 
observed except for the combination of Group 1; alkaline 
phosphatase expression with Group 2; biocompatibility 
assays, where a 95 % covariance was observed (Fig. 1a).
 Our approach has its limitations. Any cross centre 
study, especially adopting a retrospective approach, is 
subject to the significant challenge of inevitable variation 
in protocols, reagents and cell source etc. between 
laboratories. Importantly, the main readout of the current 
study, the correlation between in vitro and in vivo outcomes 
will remain fairly robust against such variation as the point 
of comparison is not between the assays conducted across 
the various groups, but between the in vitro and in vivo 
stages of biomaterial testing undertaken in each individual 
laboratory. Perhaps more problematic is the inevitably 
limited scoring system required to tabulate the large variety 
and complexity of the assays conducted. For example, 
we reduce a complex readout such as osteogenic gene 
expression to a score of high and low expression of early 
and late markers. This is indeed a significant limitation 
Table 2. In vitro assays with participating laboratories and numbers of separate studies per 
in vitro assay.
Assay Parameter name
24 separate Alkaline Phosphatase Assays from 5 laboratories Group 1
14 Biocompatibility Assays from 4 laboratories Group 2
8 Calcium Deposition data sets from 2 laboratories Group 3
20 Gene Expression data sets of early markers from 3 laboratories Group 4
22 Gene Expression data sets of late markers from 3 laboratories Group 5
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of the current approach, but such broad-brush stroke 
assessments of performance reflect the conclusions often 
drawn from in vitro assays across the biomaterial literature. 
Such assessments thus serve as the hypotheses to be tested 
by our approach. Similarly, the qualitative assessment of 
each assay outcome was conducted by the groups that 
undertook the original research, raising possible concerns 
about subjective bias in the assessment of the results. 
This needs to be acknowledged as a clear limitation in the 
interpretation of the in vitro outcome itself and subsequent 
in vivo significance, but it is precisely such interpretations 
(we contend) of the success or failure of the biomaterial in 
the in vitro assays that currently form the basis for future 
in vivo testing and translation. Thus, this very limitation 
further serves the purpose of our study to test the decision 
making process underlying the biomaterial testing pipeline 
from in vitro to in vivo assessments and, it can be noted, 
justifies the contention of this review that such a lack of 
correlation is indeed surprising.
 This surprisingly poor correlation between in vitro 
and in vivo assessments of biomaterials could be due 
to a number of further factors intrinsic to the assays 
themselves. These include cell choice, cell line, cell 
passage, and cell culture protocols, which while broadly 
similar between laboratories, can result in significantly 
different data outcomes. In a literature study, Bara et al. 
described the differences between naive MSCs and MSCs 
cultured in vitro for expansion. The authors reported a large 
effect of the isolation and culture parameters that gave 
opposing results in two clinical trials, using protocols with 
differences in density media, centrifugation steps and the 
combination of media and serum. Interestingly, the seeding 
of whole bone marrow had a positive effect on Colony 
forming unit (CFU) efficiency and telomere length of the 
Fig. 1. Correlation of 47 in vitro studies and 36 in vivo studies testing 93 materials collected from 8 universities in 
a European multicentre study. a) The overall correlation between the in vitro and in vivo outcome was analysed by 
correlating the in vitro score category to the mean of the in vivo score in that category. Same method was used on 
the in vivo score category, where the mean of the in vitro assays was correlated to their corresponding in vivo score 
category. The mean in vitro scores had a covariance of 58 % to the in vivo score. The mean in vivo scores shared 
51 % of variance with the in vitro categories. The data were sorted into subgroups of different in vitro assays. The 
subgroups were biocompatibility, alkaline phosphatase expression, calcium deposition, gene expression of early 
markers and gene expression of late markers. The in vitro outcome scores of the material were then correlated with 
the in vivo outcome scores. b) The covariance of the in vitro assay of Group 1; alkaline phosphatase expression to the 
scores of the same material in vivo correlating 24 separate studies (n = 24), c) The covariance between in vivo and 
in vitro of 12 separate in vitro assay of Group 2; biocompatibility (n = 12). d) The covariance between in vivo and 
in vitro of 8 separate in vitro assay of Group 3; calcium deposition (n = 8). e) The covariance of 18 separate in vitro 
assays of Group 4; early markers (n = 18) and f) Group 5; gene expression late markers (n = 18). All the subgroups 
were correlated to the in vivo outcome score.
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MSCs. Furthermore, a lower seeding density enhanced 
proliferation while the application of autologous serum 
had a positive effect on MSC stability and maintenance 
of the naive state. The sensitivity of these parameters and 
their significance for clinical outcome thus underlines 
the importance of standardisation of protocols in order to 
dissect differences in the response to biomaterials against 
inherent differences in MSC phenotype due to various 
expansion protocols (Bara et al., 2014).
 A further potential confounding factor, particularly for 
in vitro assays using primary cells, is the known issue of 
donor variation (Georgi et al., 2015). To try and overcome 
donor cell variation when assaying biomaterials for cell 
responses, several studies have pooled cells from multiple 
donors (Stoddart et al., 2012). This approach has the 
additional benefit of allowing larger cell numbers to be 
obtained without extensive cell expansion. Stoddart et al., 
however, questioned the usefulness of this in vitro strategy 
for predicting in vivo outcomes. Arguably, donor cell 
variation in vitro mimics the host cell variation encountered 
in vivo – a highly relevant variable for predicting in vivo 
response which is obscured by the artificial donor/host 
situation achieved through pooling multiple cell sources. 
Though experimentally more intensive, biomaterials 
should ideally be tested using single donor cells repeated 
across several donors in order to quantify the robustness 
of the biomaterial strategy against donor/host variation.
 An alternative approach to overcoming the confounding 
influence of donor cell variation is the evaluation of 
materials using cell lines. While primary cells would 
appear likely to better approximate host responses, 
including, as above, host variation, such variation in the 
absence of large multi donor analyses, makes comparison 
of cell-biomaterial responses between studies difficult. 
A key advantage afforded by the implementation of cell 
lines is the homogeneity of the cell population allowing, 
at least at the early stages of the biomaterial testing 
pipeline, relatively straightforward comparison of results 
across studies and laboratories. Furthermore, cell lines 
can often allow differentiation stage-specific responses 
to biomaterials. For example, one study comparing the 
ability of various cell lines to mimic the response of 
mature osteoblasts found the MC3T3-E1 cell line to predict 
primary osteoblast responses in vitro with high fidelity 
(Czekanska et al., 2012).
Fig. 2. The groups were combined in pairs to investigate if the combination could predict the in vivo outcome. a) 
Combined in vitro score of Group 1; alkaline phosphatase and Group 2; biocompatibility (n = 5); here a significant 
covariance of 94.5 % was seen with a p-value of 0.0055. b) Combined in vitro scores of Group 1; alkaline phosphatase 
and Group 3; calcium deposition (n = 5). c) Combined in vitro score of Group 1; alkaline phosphatase expression 
and Group 4; gene expression of early markers (n = 11). d) Combined in vitro score of Group 2; biocompatibility 
and Group 3; calcium deposition (n = 5). e) Combined in vitro score of Group 2; biocompatibility and Group 4; gene 
expression of early markers (n = 5). f) Group 4; gene expression early markers combined with Group 3; calcium 
deposition (n = 7). All group combinations except for Group 1/Group 2 and Group 1/Group 3 shared covariance of 
less than 10 %.
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 Nevertheless, even accounting for the variations in 
experimental protocols and cell sources for each assay 
method, almost all in vitro assays demonstrated the 
ability to correctly identify positive outcomes (i.e. true 
positives) to a slightly greater extent than false positives 
(i.e. incorrectly predict a positive outcome). The statistical 
power of the in vitro assay groups was variable, thus 
affecting the ability to interpret the results accurately. 
However, increasing the number of studies per in vitro 
assay group to increase the power of each predictive model 
may not necessarily improve the specificity of the model 
as evidenced by Fig. 1a, e and f. Fisher’s exact test was 
performed to further measure the sensitivity and specificity 
on the various groups; all p-values obtained were of 
statistical non-significance and thus inconclusive (Fig. 
3-4). One approach to improve the predictability would 
be to develop a system of metrics based on the combined 
score achieved through a series of in vitro assays. Thus, for 
example, the combined in vitro tests of biocompatibility 
and alkaline phosphatase expression had a strong positive 
correlation, indicating a potential benefit of in vitro assay 
combinations. The combination of groups demonstrated 
the ability to detect true positives to a greater extent than 
false positives in all groups.
 It is self-evident that a large selection of in vivo models 
are used to assess the performance of biomaterials tailored 
for bone. Each in vivo model is often slightly modified for 
the purpose of the particular study and to suit the properties 
of the biomaterial tested. Thus, the large number of in vivo 
models available can make direct comparison difficult. 
Standardised and validated defects with defined parameters 
of in vivo outcome would facilitate direct comparison and 
minimise the number of animals used (Kilkenny et al., 
2010; Reichert et al., 2009; van Griensven, 2015). It is also 
necessary to appreciate that not only do the in vivo models 
differ, but also definitions of successful bone regeneration 
differ between each study.
 We have highlighted the surprisingly poor correlation 
between in vitro success or failure and in vivo success or 
failure in biomaterial testing for bone repair. It should 
also be noted that this challenge may be relatively modest 
compared with the subsequent challenges of achieving 
successful translation from small to large animal models 
and from preclinical studies into clinical trials (van 
Fig. 3. Each study of the groups was split into quartiles to sort them into percentage of false positives, false negatives, 
true positives and true negatives where a positive result was one that scored > 2.5 and a negative result one that scored 
< 2.5. a) Illustration of the quartiles selected with score 2.5 as a cut off for testing sensitivity versus specificity. b) 
Group 1; alkaline phosphatase expression (n = 24) detected true positives to a marginally greater extent than false 
positives. c) Group 2; biocompatibility (n = 12) detected true positives to a slightly greater extent than false positives 
(50 %). d) Group 3; calcium deposition (n = 8) detected a majority of true positives 75 %. Both e) Group 4; gene 
expression early markers (n = 18) and f) Group 5; gene expression late markers (n = 18) showed a random detection 
with all four outcomes. All the groups were tested with Fisher’s exact test to further measure the sensitivity and 
specificity on the various groups; all p values obtained were of statistical non-significance.
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Fig. 4. The groups were combined in pairs to investigate if a combination could predict the in vivo outcome. Each 
study of the groups was split into quartiles to sort them into percentage of false positives, false negatives, true 
positives and true negatives where a positive result was one that scored > 2.5 and a negative result one that scored 
< 2.5. a) Group 1; alkaline phosphatase and Group 2; biocompatibility (n = 5) detected true positives and true 
negatives, b) Group 1; alkaline phosphatase and Group 3; calcium deposition (n = 5) detected 20 % false positives 
and 80 % true positives. c) Group 1; alkaline phosphatase expression and Group 4; gene expression of early markers 
(n = 11) detected a large amount of false positives 55 % compared to 36 % true positives and a small amount of 
false negatives was also detected. Both d) Group 2; biocompatibility and Group 3; calcium deposition (n = 5) and 
e) Group 2; biocompatibility and Group 4; gene expression of early markers, detected a majority of true positives 
60 %. f) Group 4; gene expression early markers combined with Group 3; calcium deposition (n = 7) had a slight 
majority of 57 % of true positives. The combination of groups demonstrated the ability to detect true positives to a 
greater extent than false positives in all groups. Fisher’s exact test was performed to further measure the sensitivity 
and specificity on the various groups; all p values obtained were of statistical non-significance and thus inconclusive.
Griensven, 2015). Critically, at each stage, increased cost 
as well as surgical and physiological complexity, challenge 
reproducibility as well as predictive power (Reichert et al., 
2009). Hackam and Redelmeier explored the translation 
of research from animals to humans and concluded that 
only about a third of highly cited preclinical articles were 
later translated to human trials (Hackam and Redelmeier, 
2006). One promising approach to addressing these 
inherent limitations of large animal models has been the 
development of humanised animal models. Humanised 
animal models may, finally, serve to improve the predictive 
power of pre-clinical assessments (Holzapfel et al., 2015).
Conclusion
While we have here noted the weakness of several 
widely used in vitro measures of biomaterial success, 
it is important to emphasise the vital importance of the 
application of in vitro assays for biomaterial testing for 
bone regenerative medicine. The growing number of 
potential biomaterials for application in bone regeneration 
strategies warrants increased research investment in the 
development of early stage assays predictive of in vivo 
success or failure in order to streamline the biomaterial 
testing pipeline towards the goal of clinical translation. The 
current inadequacies of our in vitro assays highlighted here, 
will we hope further underline the urgency of this research 
imperative and, critically, stimulate the development of 
novel approaches to biomaterial testing and appropriately 
characterised pipelines with measurable sensitivity and 
specificity for translatable in vivo outcomes. In this way, we 
hope the rather long-awaited therapeutic promise of bone 
regenerative medicine will begin to be realised.
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